Funding for this research was provided by:
Intramural Research Program, National Cancer
Received: 3 November 2017
Accepted: 13 June 2018
First Online: 22 June 2018
: Principal Investigator:R. Taylor Ripley, M.D., National Cancer Institute/CCR, NIH.10 Center Drive, CRC Room 4–3952.Bethesda, MD 20892.Phone: 301–496-2127.Taylor.Ripley@nih.gov ExternalRef removed Research Nurse/Coordinator:Cara M. Kenney, RN, OCD, CCR, NCI.10 Center Drive, CRC Room 4–3752.Bethesda, MD 20892.Phone: 240–email@example.com
: The ‘Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy’ trial was approved by the Institutional Review Board (IRB) of the National Cancer Institute, National Institutes of Health, Bethesda, MD.The consent (‘The Consent to Participate in a Clinical Research Study)’ was approved by the NCI IRB and is giving to all patients prior to enrollment. The consent reference number is based on the intramural trial number, 17-C-0135, and is available as Additional file InternalRef removed.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.